1088991-95-0
1088991-95-0
Chemical Structure
DORA-22
- CAS No.: 1088991-95-0
- Formula:C23H22F2N4O2
- Molecular Weight:424.44
IUPAC Name: (5-fluoro-2-(pyrimidin-2-yl)phenyl)((2R,5R)-5-(((5-fluoropyridin-2-yl)oxy)methyl)-2-methylpiperidin-1-yl)methanone
InChIKey: ADNQCBKNFSDDHY-HZPDHXFCSA-N
SMILES: FC1=CC(C(N2C[C@H](COC3=NC=C(F)C=C3)CC[C@H]2C)=O)=C(C4=NC=CC=N4)C=C1
Biological Activity: DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
DORA-22 | 97.67% | DORA-22 is an orally active dual orexinergic receptor antagonist, and improves the sleep disruption and memory impairment. DORA-22 can be used for study of insomnia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Gamble MC, et al. The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep. 2020;43(3):zsz241. [Content Brief]
- [2]. Lin Y, Ret al. Positive allosteric adenosine A2A receptor modulation suppresses insomnia associated with mania- and schizophrenia-like behaviors in mice. Front Pharmacol. 2023;14:1138666. Published 2023 Apr 19. [Content Brief]
